Johnson & Johnson $JNJ Stock: Cliftonlarsonallen Wealth Advisors LLC Boosts Position

Key Points

• Cliftonlarsonallen Wealth Advisors increased its Johnson & Johnson stake by 23.5% in the third quarter, bringing its holdings to 39,674 shares valued at approximately $10.5 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded third-quarter earnings expectations, reporting $2.59 in EPS and $25.4 billion in revenue, while raising its 2026 adjusted EPS guidance to $11.05–$11.15. Analysts maintain a “Moderate Buy” consensus with an average price target of $273.61.
• The company declared a quarterly dividend of $1.34 per share, or $5.36 annualized, representing an approximately 2.1% yield. Recent insider activity was less favorable, with executives selling 87,569 shares worth about $23.1 million over three months.

Cliftonlarsonallen Wealth Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 23.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,674 shares of the company's stock after acquiring an additional 7,547 shares during the period. Cliftonlarsonallen Wealth Advisors LLC's holdings in Johnson & Johnson were worth $10,503,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. National Pension Service lifted its holdings in Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company's stock valued at $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc boosted its position in Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares during the period. Elefante Mark B increased its stake in shares of Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after purchasing an additional 2,563 shares in the last quarter. Signal Advisors Wealth LLC increased its stake in shares of Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock worth $3,697,000 after purchasing an additional 6,539 shares in the last quarter. Finally, Gradient Investments LLC increased its stake in shares of Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after purchasing an additional 13,737 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. HSBC upped their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Citigroup lifted their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a research note on Monday, October 5th. Argus set a $300.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Scotiabank reissued an "outperform" rating and set a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $273.61.

Johnson & Johnson Price Performance

JNJ stock opened at $253.49 on Thursday. The firm has a 50 day moving average of $265.80 and a 200-day moving average of $249.47. The firm has a market capitalization of $610.89 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 2.54 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the firm posted $2.80 EPS. Johnson & Johnson's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's payout ratio is 62.11%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ exceeded third-quarter adjusted earnings expectations, reporting EPS of $2.59 versus a $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth engine, with reported 7.9% growth and strong demand for newer products. Johnson & Johnson reports Q3 2026 results and raises 2026 guidance
• Positive Sentiment: The company raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. The improved forecast provides support for the stock despite the quarter’s mixed details. JNJ Q3 earnings call highlights
• Positive Sentiment: JNJ declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and approximately a 2.2% yield, reinforcing its appeal to income-focused investors. Johnson & Johnson announces quarterly dividend

Insider Activity

In related news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.